Recruiting at 71 sites No phase Aortic Stenosis

Trial comparing treatments for Aortic Stenosis

Official title Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement

ClinicalTrials.gov ID: NCT04634240

What this study is testing

What it's testing
This study is testing whether doing a staged coronary procedure after a valve replacement is better than just medicine alone for people with blocked heart arteries.
Who it's for
You may be able to join if you are having a valve replacement and also have blocked heart arteries.
What's involved
You will get a valve replacement and then, if chosen, a small tube procedure to open blocked arteries. You will also take medicines and have follow‑up visits to check your heart.
Time commitment
The study lasts about 6 months, with visits after the valve replacement and at follow‑up times.
  • Which group you join is decided by chance.

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Adults

You may be able to join if

  • \- Symptomatic aortic valve stenosis prior to TAVR (NYHA Functional Class ≥ 2 OR Abnormal exercise test with severe SOB, abnormal BP response, or...
  • \- CAD defined as: at least 1 coronary artery lesion of ≥70% visual angiographic diameter stenosis in a native segment ≥2.5 mm in diameter that is...
  • \- Consensus by the Local Multidisciplinary Heart Team that the patient is suitable for elective transfemoral TAVR with a balloon expandable...
  • [AVA ≤ 1.0 cm2 OR AVA index ≤ 0.6 cm2/m2]
  • [Jet velocity ≥ 4.0 m/s OR mean gradient ≥ 40 mmHg]

You likely can't join if

  • PCI already performed within 90 days prior to TAVR or at the same time as the index transfemoral TAVR procedure
  • Planned PCI of coronary artery lesion(s)
  • Planned surgical revascularization of coronary artery lesion(s)
  • Non-cardiovascular co-morbidity reducing life expectancy to \< 5 years
  • Any factor precluding 5-year follow-up
  • Prior coronary artery bypass grafting surgery or surgical valve replacement
See the full eligibility criteria
Who can join
  • \- Symptomatic aortic valve stenosis prior to TAVR (NYHA Functional Class ≥ 2 OR Abnormal exercise test with severe SOB, abnormal BP response, or arrhythmia)
  • \- CAD defined as: at least 1 coronary artery lesion of ≥70% visual angiographic diameter stenosis in a native segment ≥2.5 mm in diameter that is not a CTO and is amenable to treatment with PCI
  • \- Consensus by the Local Multidisciplinary Heart Team that the patient is suitable for elective transfemoral TAVR with a balloon expandable transcatheter heart valve AND would receive a bypass with an anastomosis...
  • [AVA ≤ 1.0 cm2 OR AVA index ≤ 0.6 cm2/m2]
  • [Jet velocity ≥ 4.0 m/s OR mean gradient ≥ 40 mmHg]
  • patients without these criteria may undergo TAVR if the Local Multidisciplinary Heart Team concludes it is appropriate.
  • \- Successful transfemoral TAVR, defined as the implantation of a single transcatheter aortic valve within the past 96 hours with freedom from more than minimal aortic insufficiency, stroke, or major vascular...
What rules you out
  • PCI already performed within 90 days prior to TAVR or at the same time as the index transfemoral TAVR procedure
  • Planned PCI of coronary artery lesion(s)
  • Planned surgical revascularization of coronary artery lesion(s)
  • Non-cardiovascular co-morbidity reducing life expectancy to \< 5 years
  • Any factor precluding 5-year follow-up
  • Prior coronary artery bypass grafting surgery or surgical valve replacement
  • Severe mitral regurgitation (\> 3+)
  • Severe left ventricular dysfunction (LVEF \< 30%)
  • Low coronary takeoff (high risk for coronary obstruction)
  • Acute myocardial infarction within 90 days
  • Stroke or transient ischemic attack within 90 days
  • Renal insufficiency (eGFR \< 30 ml/min) and/or renal replacement Rx
  • Hemodynamic or respiratory instability

The study team makes the final eligibility decision.

Where it is enrolling

  • Huntsville, Alabama, United States
  • Phoenix, Arizona, United States
  • Palo Alto, California, United States
  • Redlands, California, United States
  • Santa Barbara, California, United States
  • Torrance, California, United States
  • Atlantis, Florida, United States
  • Jacksonville, Florida, United States
  • Miami, Florida, United States
  • Atlanta, Georgia, United States
  • Gainesville, Georgia, United States
  • Boise, Idaho, United States
  • Chicago, Illinois, United States
  • Elkhart, Indiana, United States
  • Fort Wayne, Indiana, United States
  • Kansas City, Kansas, United States
  • Overland Park, Kansas, United States
  • Wichita, Kansas, United States
  • Boston, Massachusetts, United States
  • Lansing, Michigan, United States

+ 44 more site(s).

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, not specified. The study team makes the final eligibility decision.

Where is this trial taking place?

This study is enrolling now at Huntsville, Alabama, United States; Phoenix, Arizona, United States; Palo Alto, California, United States; Redlands, California, United States; Santa Barbara, California, United States; Torrance, California, United States and 58 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.